Nanopill Platform
Diabetes (e.g., oral peptide/bio logic delivery)
Key Facts
About Toralgen
Toralgen is a private, preclinical biotech leveraging a novel nanoparticle platform derived from bile acids to enable oral delivery of complex drugs, including biologics. Founded in 2019 and backed by $8M in seed funding, the company is initially targeting diabetes and autoimmune disorders. Its core technology, born from research at Yale University, seeks to transform treatment paradigms by converting injectable therapies into convenient oral pills.
View full company profileAbout Toralgen
Toralgen is a private, preclinical biotech leveraging a novel nanoparticle platform derived from bile acids to enable oral delivery of complex drugs, including biologics. Founded in 2019 and backed by $8M in seed funding, the company is initially targeting diabetes and autoimmune disorders. Its core technology, born from research at Yale University, seeks to transform treatment paradigms by converting injectable therapies into convenient oral pills.
View full company profile